A Phase 2, Prospective, Randomized, Open-label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus- Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplant Save

Date Added
February 27th, 2018
PRO Number
Pro00072922
Researcher
Michelle Hudspeth

Silhouette
Keywords
Cancer, Cancer/Leukemia, Children's Health, Drug Studies, Men's Health, Women's Health
Summary

This study is for subjects who have been diagnosed with acute leukemia or myelodysplastic syndrome (MDS) and are a candidate for allogeneic hematopoietic stem cell transplant (HSCT). The study is being done to learn if adding defibrotide to the standard medicines for prevention of acute Graft-versus-Host Disease (aGvHD), which is called immunoprophylaxis, will help to prevent aGvHD better than using the usual immunoprophylaxis medicines alone. The investigational drug in this study is called Defibrotide. The duration of participation for each patient is approximately 6 months.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Pathogen Identification in Pediatric Hematopoietic Stem Cell Transplant Patients with Suspected Lower Respiratory Tract Infection Save

Date Added
December 6th, 2016
PRO Number
Pro00060294
Researcher
Michelle Hudspeth

Silhouette
Keywords
Adolescents, Children's Health, Immune System, Lung, Pediatrics, Transplant
Summary

This study is for patient that have been diagnosed with suspected lower respiratory tract infection. The purpose of this study is to evaluate a new test that may be able to find more lung infections than current tests can. This new test is called next-generation sequencing and looks in respiratory secretions for bacteria, viruses, fungi, and other organisms that may cause infection. We hope to learn more about the usefulness of this new test in identifying infections.

Institution
MUSC
Recruitment Contact
Thomas Hortman
864-792-9579
hortman@musc.edu

A Multicenter Pilot Study of Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Targeted Immunotherapy in Children, Adolescents and Young Adults with Poor Risk CD30+ Hodgkin Lymphoma (HL) Save

Date Added
June 7th, 2016
PRO Number
Pro00050306
Researcher
Michelle Hudspeth

Silhouette
Keywords
Cancer, Cancer/Lymphoma, Drug Studies
Summary

This study is for subjects who have been diagnosed with a type of lymph gland disease called Hodgkin Lymphoma which has come back or has not gone away after treatment, including the best treatment known for these diseases. Researchers believe subjects will benefit from an allogeneic (from another human) stem cell transplant which has been offered as a form of treatment for this disease in many other patients. After transplant we will provide a type of medication that targets the CD30+ protein, a protein that is commonly expressed in Hodgkin Lymphoma. This medication is called Brentuximab Vedotin (or Brentuximab). Subjects will be offered treatment with lower doses of chemotherapy drugs, as compared to the higher doses of chemotherapy drugs historically used in transplants for other diseases. This is known as reduced intensity therapy.The main purpose of this study is to determine the safety and outcome of following reduced intensity conditioning and allogeneic stem cell transplantation in selected patients with Hodgkin Lymphoma (specifically CD30+ HL patients) with Brentuximab Vedotin. Subjects can expect to be in this study for 3 years.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies Save

Date Added
February 3rd, 2015
PRO Number
Pro00041150
Researcher
Michelle Hudspeth

Silhouette
Keywords
Cancer/Leukemia, Cancer/Lymphoma
Summary

This clinical trial is being done to collect information about various long-term effects commonly seen in children who survive a stem cell transplant. In particular, information about renal (kidney), cardio-metabolic (heart disease and diabetes) and skeletal (bone) long-term effects will be collected for two years after transplant.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

Change_preferences

-- OR --

Create_login